Biogen (BIIB) Protective Put Calculator

Calculator · free · no signup · BIIB

Price a protective put, zero-cost collar, or put spread on Biogen. Annual cost, max loss, upside cap, tax treatment, auto-filled from current BIIB option chain.

Beta · invite-only · AlphaLatitude Inc. · Free Tools

You priced one hedge. The beta picks the right hedge structure given your full equity stack and tax situation.

Request beta access →

Related calculators: Stock Concentration Calculator

About Biogen

Biogen (BIIB) is a public Other company, incorporated in Delaware and headquartered in Cambridge, MA.

Equity grants at Biogen typically include restricted stock units (RSUs).

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.

Source: Wikipedia (CC BY-SA 4.0)

Founded in Geneva in 1978 by a group including Nobel laureates Walter Gilbert and Phillip Sharp, the company built its business on multiple sclerosis: Avonex, Tysabri, and Tecfidera, the last losing exclusivity in 2020 and taking revenue with it. Aduhelm, approved for Alzheimer's disease in 2021 over an advisory committee's objection, was commercially unsuccessful and discontinued; Leqembi with Eisai followed with clearer evidence. Spinal muscular atrophy drug Spinraza adds a rare disease franchise. Headquarters are in Cambridge, Massachusetts.

Sources: biogen.com · en.wikipedia.org

Equity comp at Biogen

  • RSUs use single-trigger vesting: shares become yours as each portion vests on schedule, and the value is taxed as ordinary income at that point. No IPO or acquisition is required.

Researched 2026-08-17.

OptionsAhoy is an independent tool and is not affiliated with, endorsed by, or sponsored by Biogen.

A protective put caps your downside on the BIIB position at a chosen floor; a zero-cost collar pays for that floor by capping the upside. This calculator prices both structures off the current BIIB option chain, with annual cost, max loss, and tax-treatment notes.

All Biogen tools → · Use the generic Protect Your Stock Calculator for any company.

Biogen equity questions

How much does it cost to hedge BIIB stock?
The cost of a protective put depends on how far below the current price you set the floor, how long the protection lasts, and BIIB's option-implied volatility. A zero-cost collar lowers that cost by selling away some upside. The calculator above prices both structures off the current BIIB option chain and shows the annual cost, maximum loss, and tax treatment.
Does Biogen grant ISOs, NSOs, or RSUs?
Equity compensation at Biogen typically takes the form of restricted stock units (RSUs). Restricted stock units are taxed as ordinary income when they vest.
Do Biogen RSUs use double-trigger vesting?
No. Biogen restricted stock units (RSUs) use single-trigger vesting: each tranche becomes yours as it vests on schedule, taxed as ordinary income at that point, with no liquidity event required.
Find another companyOther peers

One piece of the puzzle.

OptionsAhoy plans your Biogen equity alongside hedging, vesting, and de-concentration, across bullish, neutral, and bearish market scenarios. Free during beta.

Request beta access